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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The article titled ‘‘Can an oral antidiabetic (rosiglitazone) be
of beneﬁt in leukemia treatment?’’ written by Cetinkalp et al.
and published in one of the recent issues of your journal was
quite interesting (Cetinkalp et al., 2015). Here, we would like
to emphasize some points.
Pan et al. (2012) showed that, metformin and rosiglitazone
enhanced daunorubicin-induced apoptosis. Rosiglitazone
increased etoposide-induced and vincristine-induced apopto-
sis. In this study, results suggest that use of insulin to control
hyperglycemia in acute lymphoblastic leukemia patients may
contribute to anthracycline chemoresistance, while metformin
and thiazolidinediones may improve chemosensitivity to
anthracycline.
In another study it was concluded that rosiglitazone
induced apoptosis in K562 leukemia cells in vitro, and that
rosiglitazone-induced apoptosis in K562 leukemia cells was
highly correlated with activation of caspase-3, decreasing
telomerase activity, down-regulation of the anti-apoptotic
protein Bcl-2, and up-regulation of the pro-apoptotic protein
Bax (Liu et al., 2009).
In our previous study, while atorvastatin and rosiglitazone
did not affect the expression of CD38 and the level of bcl-2,
these drugs signiﬁcantly increased the level of Annexin V
(chronic lymphocytic leukemia patients-CLL-) when com-
pared with control group (p< 0.001). Both drugs signiﬁcantly
decreased the expressions of CD5 (p= 0.03) and ZAP-70
(p< 0.05) compared with control group. Atorvastatin and
rosiglitazone increased apoptosis in lymphocytes of CLL
in vitro (Yavasoglu et al., 2013).In conclusion, in the light of these studies, rosiglitazone can
provide additional support in the classical treatment of both
acute and chronic leukemia.
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